CorAssist

About CorAssist

CorAssist is a pioneering medical technology startup focused on addressing Heart Failure with Preserved Ejection Fraction (HFpEF), a condition affecting millions globally. HFpEF is a type of heart failure where the heart's ability to fill with blood is impaired, but its ability to pump blood remains normal. This condition currently lacks effective treatments, making CorAssist's work particularly significant.

CorAssist's primary innovation is a device-based treatment designed to enhance the heart's diastolic function, which is the phase when the heart fills with blood. This device operates on mechanical principles, transferring energy from the heart's contraction phase (systole) to its relaxation phase (diastole), thereby improving the heart's ability to fill with blood. Notably, the device does not require an external power source, simplifying its use and maintenance.

The device is implanted using a minimally invasive procedure known as the Trans Apical Approach, which is similar to procedures used in Transcatheter Aortic Valve Implantation (TAVI). This method allows the device to be placed on a beating heart, reducing the risks and recovery time associated with more invasive surgeries.

CorAssist primarily serves patients suffering from HFpEF, a demographic that includes over 5.7 million people in the U.S. and 20 million worldwide. The company operates in the medical technology market, specifically within the cardiovascular segment. Its business model revolves around the development, clinical testing, and eventual commercialization of its innovative device. Revenue will be generated through the sale of the device to hospitals and healthcare providers, as well as potential licensing agreements and partnerships with larger medical device companies.

In summary, CorAssist is at the forefront of developing a groundbreaking solution for HFpEF, a condition with significant unmet medical needs. By focusing on a device-based approach, the company aims to provide a much-needed treatment option for millions of patients worldwide.